Because it is believed that Alzheimer’s disease affects more people than estimated, new research is being implemented. Currently about 5.4 million suffer from Alzheimer’s disease, but the real number could be as high as 11 million. Reports from the Center of Disease Control shows an increase in the death rate of 50% over the last 15 years. These drastic findings has initiated a more thorough approach in research. One area of research involves Biomarkers, which indicates the presences of the disease before symptoms occur. Beta amyloid is a toxic protein or Biomarker that is present and builds overtime in the brains of people with Alzheimer’s disease. Through early detection, it is believed that Alzheimer’s disease can have less of a chance of developing, moreover, less of a morbidity rate. With this treat the disease before it starts approach, researchers plan to implement more studies involving individuals who are asymptomatic. Clinical trials will allow researchers the opportunity to find the root cause of Alzheimer’s disease, intervening early, using new therapies and hopefully finding a cure. Overtime, the goal of early detection and intervention, will lessen the number of individuals with Alzheimer’s disease, allowing individuals to live a longer life enjoying their loved ones.

New study on biomarkers reveals Alzheimer’s affects twice as many people as previously estimated. #HealthStatus

Key Points:

• Taking into account those that have yet to show significant symptoms, it’s not unlikely the actual number of Alzheimer’s cases in the U.S. is twice the known number.
• Clinicians assert that the best time to intercede is while patients are still asymptomatic.
• They also suggest that many drugs have failed because, while promising, they only intervened at the latest stages of the disease.